ReviewPharmaceutics2022
Recent Advances in Metal-Organic-Framework-Based Nanocarriers for Controllable Drug Delivery and Release.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Drug Delivery and Visual Monitoring of Nd(ATA)-GelMA Composite Hydrogels.Gels (Basel, Switzerland) · 2026Article
- Nanoencapsulated EO-based drug delivery for pest control: from chemistry to formulation design.Protoplasma · 2026Review
- Metal-organic framework nanoparticles induced non-apoptotic cell death: Construction, mechanisms, and cancer therapy.Materials today. Bio · 2026Review
- Hyaluronic acid-modified Fe-based metal-organic framework loaded with cisplatin for targeted lung cancer therapy.RSC advances · 2026Article
- Fluorescent Nanoporous Gene Drugs with Fenton-like Catalysis Vector Research.Nanomaterials (Basel, Switzerland) · 2026Article
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Cancer and Environmental Xenobiotics: Mechanisms, Controversies, and Innovations.Journal of xenobiotics · 2025Review
- Designing MOF-Thermogel Nanocomposites for Differential Multidrug Release in Combination Cancer Therapy.ACS applied nano materials · 2025Article
- Metallic nanomedicine in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions.MedComm · 2025Review
- Development and application of chiral separation technology based on chiral metal-organic frameworks.Journal of pharmaceutical analysis · 2025Review
- Metal compounds as antimicrobial agents: 'smart' approaches for discovering new effective treatments.RSC advances · 2025Review
- Multifunctional metal-organic frameworks as promising nanomaterials for antimicrobial strategies.Burns & trauma · 2025Review
- Nanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery.Pharmaceutics · 2024Review
- Metal-organic frameworks in drug delivery: engineering versatile platforms for therapeutic applications.RSC advances · 2024Review
- Gas Delivery Relevant to Human Health using Porous Materials.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Review
- Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials.Materials today. Bio · 2024Review
- Review
- Romanian Wild-GrowingPlants (Basel, Switzerland) · 2024Article
- Copper release by MOF-74(Cu): a novel pharmacological alternative to diseases with deficiency of a vital oligoelement.RSC advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metal-organic frameworks (MOFs) have a good designability, a well-defined pore, stimulus responsiveness, a high surface area, and a controllable morphology. Up to now, various MOFs have been widely used as nanocarriers and have attracted lots of attention in the field of drug delivery and release because of their good biocompatibility and high-drug-loading capacity. Herein, we provide a comprehensive summary of MOF-based nanocarriers for drug delivery and release over the last five years. Meanwhile, some representative examples are highlighted in detail according to four categories, including the University of Oslo MOFs, Fe-MOFs, cyclodextrin MOFs, and other MOFs. Moreover, the opportunities and challenges of MOF-based smart delivery vehicles are discussed. We hope that this review will be helpful for researchers to understand the recent developments and challenges of MOF-based drug-delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.